Pfizer Inc (PFIZ34) - Net Assets
Based on the latest financial reports, Pfizer Inc (PFIZ34) has net assets worth R$90.40 Billion BRL (≈ $17.74 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$207.62 Billion ≈ $40.74 Billion USD) and total liabilities (R$117.21 Billion ≈ $23.00 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Pfizer Inc (PFIZ34) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$90.40 Billion |
| % of Total Assets | 43.54% |
| Annual Growth Rate | 1.76% |
| 5-Year Change | 12.4% |
| 10-Year Change | 45.73% |
| Growth Volatility | 12.47 |
Pfizer Inc - Net Assets Trend (2014–2025)
This chart illustrates how Pfizer Inc's net assets have evolved over time, based on quarterly financial data. See Pfizer Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Pfizer Inc (2014–2025)
The table below shows the annual net assets of Pfizer Inc from 2014 to 2025. For live valuation and market cap data, see market value of Pfizer Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | R$86.78 Billion ≈ $17.03 Billion |
-1.95% |
| 2024-12-31 | R$88.50 Billion ≈ $17.36 Billion |
-0.89% |
| 2023-12-31 | R$89.29 Billion ≈ $17.52 Billion |
-6.66% |
| 2022-12-31 | R$95.66 Billion ≈ $18.77 Billion |
+23.91% |
| 2021-12-31 | R$77.20 Billion ≈ $15.15 Billion |
+22.08% |
| 2020-12-31 | R$63.24 Billion ≈ $12.41 Billion |
+0.15% |
| 2019-12-31 | R$63.14 Billion ≈ $12.39 Billion |
-0.41% |
| 2018-12-31 | R$63.41 Billion ≈ $12.44 Billion |
-11.08% |
| 2017-12-31 | R$71.31 Billion ≈ $13.99 Billion |
+19.76% |
| 2016-12-31 | R$59.54 Billion ≈ $11.68 Billion |
-8.39% |
| 2015-12-31 | R$65.00 Billion ≈ $12.75 Billion |
-9.25% |
| 2014-12-31 | R$71.62 Billion ≈ $14.05 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Pfizer Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 58.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | R$114.61 Billion | 132.53% |
| Common Stock | R$481.00 Million | 0.56% |
| Total Equity | R$86.48 Billion | 100.00% |
Pfizer Inc Competitors by Market Cap
The table below lists competitors of Pfizer Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pfizer Inc
NYSE:PFE
|
$147.73 Billion |
|
Banco Santander S.A
F:BSDK
|
$148.32 Billion |
|
Schneider Electric S.E.
PA:SU
|
$148.71 Billion |
|
Siemens Energy AG
F:ENR
|
$149.15 Billion |
|
Applovin Corp
NASDAQ:APP
|
$146.60 Billion |
|
Uber Technologies Inc
NYSE:UBER
|
$145.94 Billion |
|
Welltower Inc
NYSE:WELL
|
$145.81 Billion |
|
Honeywell International Inc
NASDAQ:HON
|
$145.14 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pfizer Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 88,203,000,000 to 86,476,000,000, a change of -1,727,000,000 (-2.0%).
- Net income of 7,770,000,000 contributed positively to equity growth.
- Dividend payments of 9,771,000,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$7.77 Billion | +8.99% |
| Dividends Paid | R$9.77 Billion | -11.3% |
| Other Changes | R$274.00 Million | +0.32% |
| Total Change | R$- | -1.96% |
Book Value vs Market Value Analysis
This analysis compares Pfizer Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.18x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.77x to 2.18x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | R$11.93 | R$33.09 | x |
| 2018-12-31 | R$11.09 | R$33.09 | x |
| 2019-12-31 | R$11.41 | R$33.09 | x |
| 2020-12-31 | R$11.36 | R$33.09 | x |
| 2021-12-31 | R$13.74 | R$33.09 | x |
| 2022-12-31 | R$17.03 | R$33.09 | x |
| 2023-12-31 | R$15.77 | R$33.09 | x |
| 2024-12-31 | R$15.56 | R$33.09 | x |
| 2025-12-31 | R$15.21 | R$33.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pfizer Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.99%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.42%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 2.41x
- Recent ROE (8.99%) is below the historical average (17.16%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 12.82% | 18.42% | 0.30x | 2.35x | R$2.01 Billion |
| 2015 | 10.76% | 14.25% | 0.29x | 2.59x | R$490.60 Million |
| 2016 | 12.12% | 13.66% | 0.31x | 2.88x | R$1.26 Billion |
| 2017 | 29.88% | 40.55% | 0.31x | 2.41x | R$14.18 Billion |
| 2018 | 17.59% | 27.32% | 0.26x | 2.51x | R$4.81 Billion |
| 2019 | 25.77% | 39.52% | 0.25x | 2.65x | R$9.96 Billion |
| 2020 | 15.20% | 22.94% | 0.27x | 2.44x | R$3.29 Billion |
| 2021 | 28.47% | 27.04% | 0.45x | 2.35x | R$14.26 Billion |
| 2022 | 32.80% | 31.27% | 0.51x | 2.06x | R$21.81 Billion |
| 2023 | 2.38% | 3.56% | 0.26x | 2.54x | R$-6.78 Billion |
| 2024 | 9.11% | 12.62% | 0.30x | 2.42x | R$-789.30 Million |
| 2025 | 8.99% | 12.42% | 0.30x | 2.41x | R$-877.60 Million |
Industry Comparison
This section compares Pfizer Inc's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $5,838,905,500
- Average return on equity (ROE) among peers: 3.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pfizer Inc (PFIZ34) | R$90.40 Billion | 12.82% | 1.30x | $147.67 Billion |
| Eli Lilly and Company (LILY34) | $11.59 Billion | -1.76% | 2.88x | $853.51 Billion |
| Dimed S.A. Distribuidora de Medicamentos (PNVL3) | $85.61 Million | 8.13% | 0.83x | $323.12 Million |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevna… Read more